ruxolitinib phosphate

targets

all catalysts(0)

nothing on the calendar yet

News(10)

• Mid-cap biotechs join Trump’s latest round of drug pricing deals
  Focused on Medicaid, the new pacts now involve more than just large pharmaceutical companies, but still aren’t expected to meaningfully impact drugmaker profits.
  biopharma_dive · 1mo ago
• 9 midsize drugmakers climb aboard Trump’s MFN train
  Astellas Pharma, BridgeBio, BeOne Medicines and six other large biotechs join the 17 Big Pharmas that previously signed on to President Donald Trump’s Most Favored Nation (MFN) drug pricing program…
  biospace · 1mo ago
• FDA OKs Takeda, Protagonist drug for rare blood cancer
  The clearance and broader-than-expected label for Mimrylo open up a yearly revenue opportunity for Takeda that some analysts expect to reach $2 billion or more.
  biopharma_dive · 1mo ago
• Incyte cuts early-stage cancer drug to focus on next-gen programs
  Investors are focused on Incyte’s late-stage programs as the biotech braces for the 2028 patent cliff of its leading product Jakafi.
  biospace · 2mo ago
• Incyte ditches phase 1-stage JAK inhibitor to pursue next-gen options
  Incyte has ditched a JAK2 inhibitor in phase 1 development for a rare blood cancer in favor of “next-generation” replacements.
  fiercebiotech · 2mo ago
• Racing Takeda, InnoCare reports TYK2 inhibitor win in phase 2 vitiligo trial
  A phase 2 trial of InnoCare Pharma’s TYK2 inhibitor soficitinib in nonsegmental vitiligo has hit its primary endpoint, clearing the Chinese biotech to advance into the phase 3 part of the study.
  fiercebiotech · 2mo ago
• On second try, Acadia drug gets nod from European regulators
  The influential CHMP committee also threw its support behind more than a dozen other medicines while recommending the marketing authorization for Tavneos be revoked.
  biopharma_dive · 3mo ago
• Lilly scores early positive data for new JAK drug
  Acquired through its purchase of Ajax, the drug showed encouraging effects in patients with hard-to-treat myelofibrosis. To analysts, such results could lead to competition for Incyte’s Jakafi.
  biopharma_dive · 3mo ago
• Incyte CEO sees $2B Vega deal aiding a post-Jakafi future
  Bill Meury has been in or led the C-suite of several biopharma companies that have constructed multibillion-dollar exits over the past decade: Allergan, Karuna and Anthos. Now, he’s the one buying.…
  endpoints · 4mo ago
• Incyte to buy blood disorder drug in possibly $2B deal
  Acquiring Vega Therapeutics, an offshoot of "hub-and-spoke" biotech Star Therapeutics, would give Incyte a medicine that’s in late-stage testing and designed to control bleeding.
  biopharma_dive · 4mo ago